TCL Archive In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads August 8, 1980
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive NCI audit Verifies Accuracy Of NSABP’s Lumpectomy Trial, B-06; Finds No Evidence Of Misrepresentation October 21, 1994
